Protagonist Therapeutics

Update in progress

PTGX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Protagonist Therapeutics, Inc. is a U.S. discovery and development company focused on novel therapies. It is advancing Icotyde, an oral peptide for adults and children 12+ with moderate-to-severe plaque psoriasis; Rusfertide, a hepcidin-mimetic in Phase 3 for polycythemia vera. It is also developing PN-881 (IL-17 antagonist) in early trials, PN-477 and PN-458 for obesity, PN-8047, L-4R alpha antagonist, and amylinR-based obesity agents. Founded 2006, based in Newark, California.

Company score

Sentiment: 0.57; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.34; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGM (NGM)
LocationUnited States
CEODr. Dinesh V. Patel Ph.D.
Founded2006
Employees141
Websitewww.protagonist-inc.com

Identifiers

ISINUS74366E1029
FIGIBBG002B63KM7
CUSIP74366E102
CIK0001377121